JP2005522229A - 癌に関与する蛋白質 - Google Patents

癌に関与する蛋白質 Download PDF

Info

Publication number
JP2005522229A
JP2005522229A JP2003584733A JP2003584733A JP2005522229A JP 2005522229 A JP2005522229 A JP 2005522229A JP 2003584733 A JP2003584733 A JP 2003584733A JP 2003584733 A JP2003584733 A JP 2003584733A JP 2005522229 A JP2005522229 A JP 2005522229A
Authority
JP
Japan
Prior art keywords
polypeptide
ccmp
expression
nucleic acid
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003584733A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005522229A5 (enExample
Inventor
ロバート シモン ボイド
グラハム チャールズ フレッチャー
リンゼイ ジェイ ハドソン
ソナル ペイテル
ジョナサン アレキサンダー テレット
Original Assignee
オックスフォード グライコサイエンシス （ユーケイ） リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by オックスフォード グライコサイエンシス （ユーケイ） リミテッド filed Critical オックスフォード グライコサイエンシス （ユーケイ） リミテッド
Publication of JP2005522229A publication Critical patent/JP2005522229A/ja
Publication of JP2005522229A5 publication Critical patent/JP2005522229A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57419—Specifically defined cancers of colon
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2003584733A 2002-04-09 2003-04-09 癌に関与する蛋白質 Pending JP2005522229A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0208089.3A GB0208089D0 (en) 2002-04-09 2002-04-09 Protein
PCT/GB2003/001593 WO2003087841A2 (en) 2002-04-09 2003-04-09 An ephrin-b receptor protein involved in carcinoma

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2009284833A Division JP2010101901A (ja) 2002-04-09 2009-12-16 癌に関与するタンパク質

Publications (2)

Publication Number Publication Date
JP2005522229A true JP2005522229A (ja) 2005-07-28
JP2005522229A5 JP2005522229A5 (enExample) 2006-07-06

Family

ID=9934469

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2003584733A Pending JP2005522229A (ja) 2002-04-09 2003-04-09 癌に関与する蛋白質
JP2009284833A Pending JP2010101901A (ja) 2002-04-09 2009-12-16 癌に関与するタンパク質

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2009284833A Pending JP2010101901A (ja) 2002-04-09 2009-12-16 癌に関与するタンパク質

Country Status (7)

Country Link
US (2) US7655426B2 (enExample)
EP (1) EP1497659A2 (enExample)
JP (2) JP2005522229A (enExample)
AU (1) AU2003227862B2 (enExample)
CA (1) CA2479835C (enExample)
GB (1) GB0208089D0 (enExample)
WO (1) WO2003087841A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011529691A (ja) * 2008-07-31 2011-12-15 ザ ジョンズ ホプキンス ユニバーシティー 腫瘍動態を評価するための循環変異型ｄｎａ

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2610685A1 (en) 2005-06-03 2006-12-14 Novartis Vaccines And Diagnostics, Inc. Methods of treating, diagnosing or detecting cancer using an ephb3 modulator
KR101437188B1 (ko) * 2006-08-04 2014-10-02 노바르티스 아게 Ｅｐｈｂ3-특이적 항체 및 이의 용도
EA200900767A1 (ru) * 2006-12-07 2009-12-30 Новартис Аг Антагонистические антитела против ephb3
EP4467565A3 (en) 2016-12-21 2025-03-12 Amgen Inc. Anti-tnf alpha antibody formulations

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4233782A1 (de) * 1992-10-07 1994-04-14 Chemotherapeutisches Forschungsinstitut Georg Speyer Haus Klonierung eines neuen Mitgliedes der Familie der Rezeptor-Protein-Tyrosin-Kinasen

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5506205A (en) * 1993-11-24 1996-04-09 Ono Pharmaceutical Co., Ltd. Polypeptide of protein p140 and DNAs encoding it
US5457048A (en) 1993-12-03 1995-10-10 La Jolla Cancer Research Foundation Eph-related tyrosine kinases, nucleotide sequences and methods of use
EP0756627A1 (en) 1994-04-15 1997-02-05 Amgen Inc. Hek5, hek7, hek8, hek11, new eph-like receptor protein tyrosine kinases
WO2001057188A2 (en) 2000-02-03 2001-08-09 Hyseq, Inc. Novel nucleic acids and polypeptides
AU5621501A (en) 2000-03-27 2001-10-08 Bayer Aktiengesellschaft Regulation of human ephrin-like receptor
AUPQ909100A0 (en) 2000-07-28 2000-08-24 Ludwig Institute For Cancer Research A method for diagnosis and treatment
US20030077568A1 (en) * 2000-09-15 2003-04-24 Gish Kurt C. Methods of diagnosis of colorectal cancer, compositions and methods of screening for colorectal cancer modulators
AU2002314433A1 (en) 2001-07-02 2003-01-21 Licentia Ltd. Ephrin-tie receptor materials and methods
WO2006119510A2 (en) * 2005-05-04 2006-11-09 Receptor Biologix, Inc. Isoforms of receptor for advanced glycation end products (rage) and methods of identifying and using same

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4233782A1 (de) * 1992-10-07 1994-04-14 Chemotherapeutisches Forschungsinstitut Georg Speyer Haus Klonierung eines neuen Mitgliedes der Familie der Rezeptor-Protein-Tyrosin-Kinasen

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JPN6009019446, Ｃａｎｃｅｒ Ｒｅｓ．， ｖｏｌ． ６１， ｐａｇｅｓ ３５４４−３５４９ （２００１） *
JPN6009019448, Ｏｎｃｏｇｅｎｅ， ｖｏｌ． ８， ｐａｇｅｓ ２８５７−２８６２ （１９９３） *
JPN6009019450, Ｃｌｉｎ． Ｃａｎｃｅｒ Ｒｅｓ．， ｖｏｌ． ５， ｐａｇｅｓ ４５５−４６０ （１９９９） *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011529691A (ja) * 2008-07-31 2011-12-15 ザ ジョンズ ホプキンス ユニバーシティー 腫瘍動態を評価するための循環変異型ｄｎａ

Also Published As

Publication number Publication date
WO2003087841A3 (en) 2004-02-26
JP2010101901A (ja) 2010-05-06
US20110150877A1 (en) 2011-06-23
CA2479835A1 (en) 2003-10-23
AU2003227862A1 (en) 2003-10-27
US20050260209A1 (en) 2005-11-24
WO2003087841A2 (en) 2003-10-23
GB0208089D0 (en) 2002-05-22
EP1497659A2 (en) 2005-01-19
AU2003227862B2 (en) 2008-08-28
US7655426B2 (en) 2010-02-02
CA2479835C (en) 2013-10-01

Similar Documents

Publication Publication Date Title
JP4446036B2 (ja) 上皮誘導性癌の治療のための薬剤組成物
JP2010518847A (ja) タンパク質
JP4532273B2 (ja) 癌に関係するタンパク質
JP2010101901A (ja) 癌に関与するタンパク質
AU2004285339B2 (en) A protein involved in ovarian cancer
US20060088537A1 (en) Protein involved in cancer
US20070142276A1 (en) Protein involved in carcinoma
JP2010117358A (ja) 癌に関与するタンパク質
US7297760B2 (en) Cancer associated protein
US20070141061A1 (en) Protein involved in carcinoma
US20040166517A1 (en) Cancer associated protein
GB2388113A (en) B-cell malignancy-associated protein

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060407

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060407

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090427

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090710

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20090817

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091216

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20091216

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20091216

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100224

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100409

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20100415

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20100514